ReviewInternational journal of molecular sciences2021
Clinical and Molecular Biomarkers for Diagnosis and Staging of NAFLD.
Review in International journal of molecular sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 70 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
70 citing papers in PubMed, 1 synthesis or guideline pooled it, 96 citations in OpenAlex.
- MAST versus FAST for active fibrotic MASH: a meta-analysis supporting risk-stratified diagnostic pathways.Frontiers in medicine · 2026Pooled it
- Efficacy and serum metabolomic analysis of Jiu Wei Qingzhi Formula in treating non-alcoholic fatty liver disease: study protocol for a parallel-armed, randomized controlled trial.Naunyn-Schmiedeberg's archives of pharmacology · 2026Trial
- miR-34a and miR-223 as diagnostic biomarkers for the severity of non-alcoholic fatty liver disease.Journal, genetic engineering & biotechnology · 2026Article
- MicroRNA Crosstalk in Metabolic Disorders: The Dual Role of miR-122 and miR-34a in NAFLD and Type 2 Diabetes.Molecular biotechnology · 2026Review
- Mitochondrial Dysfunction in Metabolic-Syndrome-Related MASLD/MASH: Metabolic Mechanisms and Therapeutic Perspectives.Metabolites · 2026Review
- Physiologically relevant media are associated with overlapping metabolic responses in primary human hepatocytes and Huh7 cells.Physiological reports · 2026Article
- Diagnostic Value of Serum Fibroblast Growth Factor 21 Combined with Fibrosis-4 Index for Hepatic Fibrosis in Metabolic Dysfunction-Associated Steatotic Liver Disease.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2026Article
- From bench to bedside: Molecular mechanisms, diagnostic tools, and therapeutic strategies in liver fibrosis.Liver research (Beijing, China) · 2026Review
- Plasma cell-free transcriptome profiling in blood plasma from chronic liver disease patients.Scientific data · 2026Article
- Circulating MicroRNA Profiling for Phenotypic Stratification in Patients with Metabolic Dysfunction-Associated Fatty Liver Disease: A Candidate-Based Study.Current issues in molecular biology · 2026Article
- Analysis of risk factors and establishment of a predictive model for liver disease severity in metabolic dysfunction-associated fatty liver disease.Frontiers in medicine · 2026Article
- Lipid metabolism-MAFLD crosstalk: mechanisms and therapy.Frontiers in endocrinology · 2026Review
- Epidemiological Transition of Nonalcoholic Fatty Liver Disease and Cirrhosis in Asia: Three Decades of Spatiotemporal Dynamics, Health Inequality, and Future Burden.Canadian journal of gastroenterology & hepatology · 2026Article
- A panel of miRNAs in serum extracellular vesicles serves as novel diagnostic biomarkers for MASLD.Biomedical journal · 2025Article
- Circulating miR-122-5p, miR-151a-3p, miR-126-5p and miR-21-5p as potential predictive biomarkers for Metabolic Dysfunction-Associated Steatotic Liver Disease assessment.Journal of physiology and biochemistry · 2025Article
- Metabolic and hepatic effects of semaglutide and empagliflozin on metabolic dysfunction-associated steatotic liver disease mice.World journal of hepatology · 2025Article
- Machine Learning-Based Biomarker Identification for Early Diagnosis of Metabolic Dysfunction-Associated Steatotic Liver Disease.The Journal of clinical endocrinology and metabolism · 2025Article
- Biomarker Discovery for Metabolic Dysfunction-associated Steatotic Liver Disease Utilizing Mendelian Randomization, Machine Learning, and External Validation.Journal of clinical and translational hepatology · 2025Article
- The association between cardiometabolic index (CMI) and metabolic dysfunction-associated steatotic liver disease (MASLD): a systematic review and meta-analysis.Diabetology & metabolic syndrome · 2025Review
- Metabolic Dysfunction-Associated Steatohepatitis Diagnosis and Management in Germany: Insights From an Expert Consensus Panel.Liver international : official journal of the International Association for the Study of the Liver · 2025Article
10 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Non-alcoholic fatty liver disease (NAFLD) is the most common hepatic pathology in industrialized countries, affecting about 25% of the general population. NAFLD is a benign condition, however, it could evolve toward more serious diseases, including non-alcoholic steatohepatitis (NASH), fibrosis, cirrhosis, and finally, hepatocellular carcinoma (HCC). Liver biopsy is still the gold standard for NAFLD diagnosis. Due to the risks associated with liver biopsy and the impossibility to apply it on a large scale, it is now necessary to identify non-invasive biomarkers, which may reliably identify patients at higher risk of progression. Therefore, several lines of research have tried to address this issue by identifying novel biomarkers using omics approaches, including lipidomics, metabolomics and RNA molecules' profiling. Thus, in this review, we firstly report the conventional biomarkers used in clinical practice for NAFL and NASH diagnosis as well as fibrosis staging, and secondly, we pay attention to novel biomarkers discovered through omics approaches with a particular focus on RNA biomarkers (microRNAs, long-noncoding RNAs), showing promising diagnostic performance for NAFL/NASH diagnosis and fibrosis staging.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.